Thymosin Alpha-1

Overview

Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide originally isolated from thymic tissue (Thymosin Fraction 5) by Allan Goldstein at the George Washington University in the 1970s. It is a naturally occurring peptide that plays a central role in thymic T-cell maturation and immune system regulation. A synthetic version (thymalfasin) is approved as a pharmaceutical agent in multiple countries outside the United States.

Research Summary

Thymosin Alpha-1 has one of the most extensive research bases of any immunomodulatory peptide, with studies spanning from basic immunology to clinical applications. Preclinical research has documented its role in T-cell maturation, dendritic cell activation, and modulation of Th1/Th2 balance. It has been studied in animal models of infection, immunodeficiency, and vaccine adjuvancy. The synthetic pharmaceutical form (thymalfasin, brand name Zadaxin) has been used in over 35 countries for various research and clinical applications. Published clinical research includes studies on hepatitis B and C, immunodeficiency states, and vaccine enhancement.

Proposed Mechanism of Action

Thymosin Alpha-1 acts through Toll-like receptor (TLR) signaling, particularly TLR2, TLR7, and TLR9, on dendritic cells and other antigen-presenting cells. It promotes T-cell differentiation and maturation, enhances NK cell activity, modulates cytokine production (increasing IL-2, IFN-α, and IFN-γ), and promotes MHC class I antigen presentation. Its effects on adaptive immunity appear mediated through dendritic cell activation and subsequent T-helper cell polarization.

Vendor Availability

Published Research References

References are provided for informational purposes. PeptiNox does not endorse or validate the conclusions of cited studies. All listed research pertains to preclinical or in vitro investigations unless otherwise noted.